Atorvastatin, Clopidogrel and Aspirin Capsules - Manufacturers & Suppliers - Third Party Contract Manufacturing - PCD Pharma Franchise
CORAVAS Gold 20 includes Atorvastatin 10mg, Clopidogrel 75 mg and Aspirin 75 mg.
Atorvastatin belongs to ‘statin’ class of drugs. These drugs are used in maintaining the lipid profile and prevents the events associated with cardiovascular diseases.
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.
Aspirin is used to prevent a first heart attack in people with heart disease risk factors, such as diabetes and high cholesterol.
• It is indicated in the management of primary hypercholesterolemia, combined hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia
Mechanism of action
Atorvastatin produces its action by acting as HMG Co A enzyme inhibition which converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, which is a precursor of cholesterol and sterols.
Clopidogrel is metabolized to its active form by carboxylesterase-1.The active form is a platelet inhibitor that irreversibly binds to P2Y12 ADP receptors on platelets. This binding prevents ADP binding to P2Y12 receptors, activation of the glycoprotein GPIIb/IIIa complex, and platelet aggregation.
As prescribed by the physician.
Atorvastatin attains its peak plasma concentration attains in 1-2 hrs after oral administration. The bioavailability of the drug is approximately 14%. The presence of food affects the drug availability.
A 75mg oral dose of clopidogrel is 50% absorbed from the intestine. The active metabolite of clopidogrel reaches a maximum concentration after 30-60 minutes.
Atorvastatin’s nearly about 98% of the drug is bound to plasma protein. The drugs produce its action by forming its metabolites.
The apparent volume of distribution of clopidogrel is 39,240±33,520L.
After pharmacological action Atorvastatinis excreted through bile. The elimination half life is 14 hrs.
An oral dose of radiolabelled clopidogrel is excreted 50% in the urine and 46% in the feces over 5 days.
• Patients with hepatic dysfunction
• Increase in fasting glucose level
• In pregnant and lactating mothers
• Hypersensitivity to any of the ingredient
• In lactating and pregnant mothers
Hypersensitivity to the active substance or to any of the excipients